Organoprotecive effects of angiotensin II receptor blockers in patients with type 2 diabetes mellitus

Organoprotecive effects of angiotensin II receptor blockers in patients with type 2 diabetes mellitus

High prevalence of arterial hypertension and related cardiovascular complications dictates the necessity of preparations possessed of markedorganoprotective activity and good tolerability. The currently available data suggest advantages of iACE and ARB as preparations for the treatmentof cardiovascu...

Full description

Bibliographic Details
Main Authors:	Ivona Yanovna Yarek-Martynova, Minara Shamkhalovna Shamkhalova
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2010-06-01
Series:	Сахарный диабет
Subjects:	telmisartan angiotensin ii ontarget transcend
Online Access:	https://www.dia-endojournals.ru/jour/article/view/5675

Similar Items

ANGIOTENSIN RECEPTOR BLOCKERS WITH PLEIOTROPIC PROPERTIES: A NEW STANDARD IN CARDIOVASCULAR RISK MANAGEMENT AND TREATMENT OF HYPERTENSION
by: V. I. Podzolkov, et al.
Published: (2017-07-01)

FROM HOPE TRIAL TO ONTARGET TRIAL: THE «HOPE» TO REACH THE «TARGET» - TO IMPROVE PROGNOSIS IN HIGH RISK PATIENTS
by: Yu. M. Lopatin
Published: (2016-01-01)

Angiotensin receptor blocker telmisartan: efficacy, safety and relevance of clinical application
by: Maksimov M.L., et al.
Published: (2017-02-01)

Angiotensin receptor blockers: rational prescription tailored to the cardiovascular risk and comorbidities
by: V. I. Podzolkov, et al.
Published: (2018-12-01)

Molecular targeting therapy with angiotensin II receptor blocker for prostatic cancer
by: Hiroji Uemura, et al.
Published: (2011-12-01)

Molecular targeting therapy with angiotensin II receptor blocker for prostatic cancer
by: Hiroji Uemura, et al.
Published: (2011-12-01)

Chronic Lithium Toxicity in Old Age Patients Taking Angiotensin Receptor Blocker: A Case Report
by: Asim Pandey, et al.
Published: (2023-11-01)

Effects of two different angiotensin receptor blockers on blood glucose level and HbA1c in type-2 diabetes mellitus patients with hypertension
by: Shafat Iqbal Bhati, et al.
Published: (2023-10-01)

TELMISARTAN IN THE TREATMENT OF ARTERIAL HYPERTENSION. CASE STUDY
by: V. I. Podzolkov, et al.
Published: (2015-12-01)

Effect of angiotensin receptor blockers and angiotensin‐converting enzyme 2 on plasma equilibrium angiotensin peptide concentrations in cats with heart disease
by: Terry Huh, et al.
Published: (2021-01-01)

Central blood pressure lowering effect of telmisartan‐rosuvastatin single‐pill combination in hypertensive patients combined with dyslipidemia: A pilot study
by: JungMin Choi, et al.
Published: (2021-09-01)

Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers—Relevance to COVID-19
by: Graham J. Moore, et al.
Published: (2021-07-01)

From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy
by: John Matsoukas, et al.
Published: (2021-01-01)

ACE INHIBITORS AND ANGIOTENSIN II RECEPTOR BLOCKERS IN THE TREATMENT OF CARDIOVASCULAR DISEASE: WHAT TO CHOOSE?
by: K. A. Ghyamdzhyan, et al.
Published: (2022-12-01)

Immunomodulatory Activity of the Most Commonly Used Antihypertensive Drugs—Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
by: Paweł Bryniarski, et al.
Published: (2022-02-01)

The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects
by: Hirotetsu Takagi, et al.
Published: (2021-03-01)

Potential use of angiotensin receptor blockers in skin pathologies
by: Keshvad Hedayatyanfard, et al.
Published: (2023-07-01)

Issledovanie ONTARGET: Telmisartan ne ustupaet po effektivnosti ramiprilu u patsientov s vysokim riskom serdechno-sosudistykh oslozhneniy / sakharnym diabetom
by: Olga Konstantinovna Vikulova, et al.
Published: (2008-06-01)

Cardiometabolic properties of telmisartan: new perspectives for use
by: O. M. Drapkina, et al.
Published: (2015-12-01)

An Emerging Strategy for Neuroinflammation Treatment: Combined Cannabidiol and Angiotensin Receptor Blockers Treatments Effectively Inhibit Glial Nitric Oxide Release
by: Sigal Fleisher-Berkovich, et al.
Published: (2023-11-01)

Beneficial Effect of Mas Receptor Deficiency on Vascular Cognitive Impairment in the Presence of Angiotensin II Type 2 Receptor
by: Akinori Higaki, et al.
Published: (2018-02-01)

Angiotensin II Type 1 Receptor Blocker Prevents Abdominal Aortic Aneurysm Progression in Osteoprotegerin‐Deficient Mice via Upregulation of Angiotensin (1–7)
by: Kohei Karasaki, et al.
Published: (2023-02-01)

Angiotensin II modulates THP-1-like macrophage phenotype and inflammatory signatures via angiotensin II type 1 receptor
by: Tlili Barhoumi, et al.
Published: (2023-08-01)

Association of Renin-Angiotensin System Blockers with Survival in Patients on Maintenance Hemodialysis
by: Seok Hui Kang, et al.
Published: (2023-05-01)

Angiotensin II Receptor Blockers and Arrhythmias in Ventricular Hypertrophy
by: Guy Salama
Published: (2022-08-01)

Angiotensin II Receptor Blockers Reduce Tau/Aß42 Ratio: A Cerebrospinal Fluid Biomarkers’ Case-Control Study
by: Gemma García-Lluch, et al.
Published: (2023-03-01)

Clinical pharmacogenetics of angiotensin II receptor blockers in Iraq
by: Hany A Al-Hussaniy, et al.
Published: (2023-01-01)

INHIBITION OF KIDNEY DISORDERS IN CARDIOVASCULAR DISEASES: THE ROLE OF ANGIOTENSIN II RECEPTOR BLOCKERS
by: V. V. Fomin
Published: (2016-01-01)

The impact of different angiotensin II receptor blockers on the stiffness of the large arteries and effectiveness of therapy
by: O. L. Rekovets, et al.
Published: (2022-12-01)

Clinical pharmacology of angiotensin II receptor blockers: valsartan
by: M. V. Leonova
Published: (2014-12-01)

Angiotensin receptor blockers in heart failure after the ELITE II trial
by: Willenheimer Ronnie
Published: (2000-09-01)

Perioperative management of angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers: a survey of perioperative medicine practitioners
by: Sophie L.M. Walker, et al.
Published: (2018-06-01)

Neuroprotective effect of angiotensin II receptor blockers on the risk of incident Alzheimer’s disease: A nationwide population-based cohort study
by: Hyun Woo Lee, et al.
Published: (2023-03-01)

Actions of Novel Angiotensin Receptor Blocking Drugs, Bisartans, Relevant for COVID-19 Therapy: Biased Agonism at Angiotensin Receptors and the Beneficial Effects of Neprilysin in the Renin Angiotensin System
by: Graham J. Moore, et al.
Published: (2022-07-01)

Therapeutic targets in the brain for overactive bladder: A focus on angiotensin II type 1 receptor
by: Shogo Shimizu
Published: (2023-10-01)

Effect of Angiotensin II on Chondrocyte Degeneration and Protection via Differential Usage of Angiotensin II Receptors
by: Takashi Nishida, et al.
Published: (2021-08-01)

Effect of the renin-angiotensin system on the exacerbation of adrenal glucocorticoid steroidogenesis in diabetic mice: Role of angiotensin-II type 2 receptor
by: Amanda da Silva Chaves, et al.
Published: (2022-11-01)

ANGIOTENSIN II RECEPTOR TYPE 1 EXPRESSION IN PATIENTS WITH MULTIFOCAL ATHEROSCLEROSIS
by: I. S. Mykhailichenko
Published: (2016-04-01)

Glucose-lowering therapies in patients with diabetes mellitus and chronic kidney disease
by: Minara Shamkhalovna Shamkhalova, et al.
Published: (2013-09-01)

Angiotensin II type 1 receptor blockers prevent aortic arterial stiffness in elderly patients with hypertension
by: Mo-Li Zhu, et al.
Published: (2019-10-01)